Skip To Main Content
Lilly
Menu closed
Lilly
    Lilly

    You are now leaving the LillyMedical website

    The link you clicked on will take you to a site maintained by a third party, which is solely responsible for its content. Lilly USA, LLC does not control, influence, or endorse this site, and the opinions, claims, or comments expressed on this site should not be attributed to Lilly USA, LLC. Lilly USA, LLC is not responsible for the privacy policy of any third-party websites. We encourage you to read the privacy policy of every website you visit.
    Click "Continue" to proceed or "Return" to return to LillyMedical.

    Oncology Journal Publications

    This page includes links to Lilly sponsored trials and observational research that have been published in peer reviewed journals within the last 5 years. Each section is sorted by product and may be expanded for more information. The list of publications below is limited to products that have been approved for use and may contain information about doses, delivery devices, uses, formulations and populations different from product labeling. Clinical decisions should be based on the full safety and efficacy information contained in the product's Full Prescribing Information in the provided link below.

    If you have questions about a Lilly study not listed below or would like to request an electronic copy of one of the journal publications on this page, please call 1-800-LILLYRX (1-800-545-5979). For our publication linking statement click here

    For all other requests, please visit our Contact Lilly services.

    Alimta® (pemetrexed for injection)

    Full Prescribing Information

    No Publication Journals

    No Publication Journals

    No Publication Journals

    No Publication Journals

    Cyramza® (ramucirumab)

    Full Prescribing Information

    No Publication Journals

    No Publication Journals

    Efficacy and Safety of Ramucirumab in Asian and Non-Asian Patients with Advanced Hepatocellular Carcinoma and Elevated Alpha-Fetoprotein: Pooled Individual Data Analysis of Two Randomized Studies
    Published Date: May 15, 2020

    No Publication Journals

    Risk Thresholds for Patients to Switch Between Daily Tablets and Biweekly Infusions in Second-Line Treatment for Advanced Hepatocellular Carcinoma: a Patient Preference Study
    Published Date: January 19, 2023
    Real-world Molecular Biomarker Testing Patterns and Results for Advanced Gastroesophageal Cancers in the United States
    Published Date: February 23, 2023
    Real-world ramucirumab and immune checkpoint inhibitor sequences in US patients with advanced gastroesophageal cancer
    Published Date: May 17, 2023
    Patient Characteristics, Testing and Treatment Patterns, and Outcomes in EGFR-mutated Advanced Non-Small Cell Lung Cancer: A Multinational, Real-World Study
    Published Date: May 25, 2023
    Efficacy and safety of first-line therapies in EGFR-mutated advanced non-small-cell lung cancer: a network meta-analysis.
    Published Date: February 23, 2022
    TP53 Co-Mutation Status Association with Clinical Outcomes in Patients with EGFR-Mutant Non-Small Cell Lung Cancer
    Published Date: December 12, 2022
    Treatment sequencing for the care of patients with advanced or metastatic  non-small cell lung cancer in the United States
    Published Date: February 2, 2021
    Treatment Patterns for Patients with Advanced/Metastatic Cancers by Site-of-Care
    Published Date: April 12, 2021
    Data Integration to Improve Real-world Health Outcomes Research for Non-Small Cell Lung Cancer in the United States: Descriptive and Qualitative Exploration.
    Published Date: April 12, 2021
    Real-World Characteristics and Outcomes of Advanced NSCLC Patients With EGFR Exon 19 Deletions or Exon 21 Mutations
    Published Date: April 19, 2021
    Study of patient characteristics, treatment patterns, EGFR testing patterns and outcomes in real-world patients with EGFRm+ NSCLC
    Published Date: October 12, 2021

    Erbitux® (cetuximab)

    Full Prescribing Information

    No Publication Journals

    No Publication Journals

    No Publication Journals

    No Publication Journals

    Jaypirca® (pirtobrutinib)

    Full Prescribing Information

    Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 study.
    Published Date: March 4, 2022

    No Publication Journals

    No Publication Journals

    No Publication Journals

    Outcomes Among Patients with Mantle Cell Lymphoma post-covalent BTK Inhibitor Therapy in the United States: A Real-World Electronic Medical Records Study
    Published Date: December 28, 2022

    Portrazza® (necitumumab)

    Full Prescribing Information

    No Publication Journals

    No Publication Journals

    Retevmo® (selpercatinib)

    Full Prescribing Information

    No Publication Journals

    No Publication Journals

    Real-World Biomarker Testing Patterns in Patients With Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) in a US Community-Based Oncology Practice Setting.
    Published Date: March 20, 2023
    Diagnostic characteristics, treatment patterns, and clinical outcomes for patients with advanced/metastatic medullary thyroid cancer
    Published Date: February 12, 2022
    Diagnostic Value and Cost-Effectiveness of Next Generation Sequencing-Based Testing for Treatment of Patients with Advanced/Metastatic Non-Squamous Non-Small Cell Lung Cancer in the United States.
    Published Date: July 28, 2022
    Biomarker Testing for Patients With Advanced/Metastatic Nonsquamous NSCLC in the United States of America, 2015 to 2021
    Published Date: August 15, 2022
    Costs of biomarker testing among patients with metastatic lung or thyroid cancer in the USA: a real-world commercial claims database study.
    Published Date: December 8, 2022
    Characteristics and outcomes of patients with RET-fusion positive non-small lung cancer in real-world practice in the United States.
    Published Date: February 9, 2021

    Verzenio® (abemaciclib)

    Full Prescribing Information

    No Publication Journals

    No Publication Journals

    No Publication Journals

    Characteristics and Outcomes in US Male Patients (Pts) with Metastatic Breast Cancer (MBC) Receiving Abemaciclib (Abema) in Routine Clinical Practice
    Published Date: April 2, 2023
    Treatment patterns and outcomes associated with sequential and non-sequential use of CDK4 & 6 inhibitors in patients with HR+, HER2- MBC in the real world
    Published Date: June 14, 2023
    Breast cancer-specific mortality in early breast cancer as defined by high-risk clinical and pathologic characteristics.
    Published Date: March 1, 2022
    Adjuvant Abemaciclib Combined With Endocrine Therapy for High Risk Early Breast Cancer: Safety and Patient-Reported Outcomes From the monarchE Study
    Published Date: March 22, 2022
    A real-world retrospective study of the use of Ki-67 testing and treatment patterns in HR+, HER2- early breast cancer patients in the United States.
    Published Date: May 6, 2022
    Real world incidence and management of adverse events in patients with HR+, HER2- metastatic breast cancer receiving CDK4 and 6 inhibitors in a United States community setting.
    Published Date: May 10, 2022
    A real-world US study of recurrence risks using combined clinicopathological features in HR-positive, HER2-negative early breast cancer
    Published Date: May 25, 2022
    Real-world patient characteristics, utilization patterns, and outcomes of US patients with HR+/HER2- metastatic breast cancer treated with abemaciclib
    Published Date: September 22, 2022
    Patient characteristics, treatment patterns, and outcomes of hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer patients prescribed cyclin-dependent kinase 4 and 6 inhibitors: large-scale data analysis using a Japanese claims database
    Published Date: November 21, 2022
    Development of a Prognostic Factor Index among Women with HR+/HER2- Metastatic Breast Cancer in a Community Oncology Setting
    Published Date: March 4, 2021
    Real-world treatment patterns and outcomes of abemaciclib for the treatment of HR+, HER2- metastatic breast cancer.
    Published Date: May 10, 2021
    Predicting Optimal Treatment Regimens for patients with HR+/HER2- Breast Cancer Using Machine Learning Based on Electronic Health Records
    Published Date: June 8, 2021
    Real-world clinical profile, treatment patterns and patient-reported outcomes in a subset of HR+/HER2− advanced breast cancer patients with poor prognostic factors: data from an international study
    Published Date: August 7, 2021
    Prognostic Factors in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative (HR+/HER2-) Advanced Breast Cancer: A Systematic Literature Review
    Published Date: August 20, 2021
    Treatment Experiences with CDK4&6 Inhibitors Among Women with Metastatic Breast Cancer: A Qualitative Study.
    Published Date: November 3, 2021
    KRAS mutation as a prognostic factor and effect modifier in advanced/metastatic non-small cell lung cancer: A systematic literature review and meta-analysis
    Published Date: July 25, 2020
    Treatment patterns, adverse events, and direct and indirect economic burden in a privately insured population of patients with HR+/HER2- metastatic breast cancer in the United States
    Published Date: August 5, 2020

    Can't find what you're looking for? Contact us for answers to your medical questions.

    • Copyright
    • Terms of Use
    • Privacy Statement
    • Consumer Health Privacy Notice
    • Accessibility Statement
    • Sitemap
       

      This site is intended for US Healthcare Professionals only.

      4.0.66 5/2025 | GLOOTH00001 04/2015 | © Lilly USA, LLC 2025. All rights reserved.

      Product names listed above are trademarks or registered trademarks owned by or licensed to Eli Lilly and Company, its subsidiaries, or affiliates

      California Consumer Privacy Act (CCPA) Opt-Out Icon Your Privacy Choices
      Cookie Settings
      Facebook X LinkedIn
      Lilly